Literature DB >> 12071937

Somatic hypermutation and V(H) gene usage in mantle cell lymphoma.

Mia Thorsélius1, Sarah Walsh, Inger Eriksson, Ulf Thunberg, Anna Johnson, Carin Backlin, Gunilla Enblad, Christer Sundström, Göran Roos, Richard Rosenquist.   

Abstract

Mantle cell lymphoma (MCL) is considered to derive from naïve, pregerminal center (GC) CD5+ B-cells. However, the cell of origin has been questioned in recent studies that showed somatic hypermutations in the immunoglobulin (Ig) variable heavy chain (V(H)) genes in subsets of MCL. To clarify this issue, we analyzed the IgV(H) genes for the presence of somatic hypermutations in 51 MCL cases. Twenty percent of the MCL cases displayed somatically mutated V(H) genes (defined as >2% mutated), whereas 80% showed unmutated V(H) genes. This finding suggests that MCL is a genetically heterogeneous disease, with the majority of cases originating from unmutated pre-GC B-cells and a subset deriving from more mature B-cells which have been exposed to the GC environment and have undergone somatic hypermutation. A biased V(H) gene usage has been demonstrated in several B-cell malignancies; however, this has not yet been investigated in MCL, although V(H)4-34 overusage has been indicated by small studies. Interestingly, we found a restricted usage of three individual V(H) genes in our MCL material; V(H)4-34 (22%), V(H)3-21 (16%) and V(H)5-51 (12%). This novel finding of preferential V(H) gene usage in half of the MCL cases may suggest an antigen driven process occurring in B-cells expressing specific VH genes, thus implicating that Ig specificity could be involved in mantle cell lymphoma development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12071937     DOI: 10.1034/j.1600-0609.2002.01662.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  21 in total

Review 1.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 3.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

4.  Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.

Authors:  Samuel G Katz; James L Labelle; Hailong Meng; Regina P Valeriano; Jill K Fisher; Heather Sun; Scott J Rodig; Steven H Kleinstein; Loren D Walensky
Journal:  Blood       Date:  2013-12-18       Impact factor: 22.113

5.  A novel human B cell subpopulation representing the initial germinal center population to express AID.

Authors:  Grant R Kolar; Darshna Mehta; Rosana Pelayo; J Donald Capra
Journal:  Blood       Date:  2006-11-28       Impact factor: 22.113

Review 6.  Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis.

Authors:  Sarah H Walsh; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

7.  Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

Authors:  Patricia Pérez-Galán; Helena Mora-Jensen; Marc A Weniger; Arthur L Shaffer; Edgar G Rizzatti; Colby M Chapman; Clifton C Mo; Lawrence S Stennett; Christoph Rader; Poching Liu; Nalini Raghavachari; Maryalice Stetler-Stevenson; Constance Yuan; Stefania Pittaluga; Irina Maric; Kieron M Dunleavy; Wyndham H Wilson; Louis M Staudt; Adrian Wiestner
Journal:  Blood       Date:  2010-10-18       Impact factor: 22.113

8.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

Review 9.  Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.

Authors:  Sylvia Hoeller; Yi Zhou; Rashmi Kanagal-Shamanna; Zijun Y Xu-Monette; Daniela Hoehn; Michel Bihl; Steven H Swerdlow; Andreas Rosenwald; German Ott; Jonathan Said; Cherie H Dunphy; Carlos E Bueso-Ramos; Pei Lin; Michael Wang; Roberto N Miranda; Alexander Tzankov; L Jeffrey Medeiros; Ken H Young
Journal:  Hum Pathol       Date:  2012-08-31       Impact factor: 3.466

10.  A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells.

Authors:  Henrik Stranneheim; Lukas M Orre; Janne Lehtiö; Jenny Flygare
Journal:  Proteome Sci       Date:  2009-11-23       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.